Sakakibara N, Click R E, Sakakibara K, Aziz S, Jamieson S W, Wick M R
Altick Associates, River Falls, Wisconsin.
Lab Invest. 1990 Apr;62(4):481-6.
In this report, the efficacy of cyclosporine A and two monoclonal antibodies, anti-L3T4 and anti-Lyt-2.2, was assessed on first-set rejection of cardiac xenografts. Neither cyclosporine nor anti-Lyt-2.2 monoclonal antibody prolonged the survival of heart xenografts. Anti-L3T4 enhanced acceptance of rat hearts transplanted to C57BL/6 mice 5-fold relative to that observed in control recipients; it did not, however, prolong acceptance of hamster hearts transplanted to mice. Histologic analysis indicated that the cellular infiltrate within rejected hearts was composed of greater than 95% lymphocytes; of these, greater than 99% were Thy-1- and sIg-. These results suggest that rejection of xenogeneic hearts is mediated by unconventional lymphoid cells. This is discussed in the context of whether rejection of allografts and xenografts occur by similar or dissimilar mechanisms.
在本报告中，评估了环孢素A以及两种单克隆抗体（抗L3T4和抗Lyt-2.2）对心脏异种移植首次排斥反应的疗效。环孢素和抗Lyt-2.2单克隆抗体均未延长心脏异种移植的存活时间。抗L3T4使移植到C57BL/6小鼠体内的大鼠心脏的接受度相对于对照受体提高了5倍；然而，它并未延长移植到小鼠体内的仓鼠心脏的接受时间。组织学分析表明，被排斥心脏内的细胞浸润由超过95%的淋巴细胞组成；其中，超过99%为Thy-1和sIg阴性。这些结果表明，异种心脏的排斥反应是由非常规淋巴细胞介导的。本文将在同种异体移植和异种移植的排斥反应是通过相似还是不同机制发生的背景下对此进行讨论。
